dc.contributor.author | Kissling, Esther | |
dc.contributor.author | Valenciano, Marta | |
dc.contributor.author | Pozo Sanchez, Francisco | |
dc.contributor.author | Vilcu, Ana-Maria | |
dc.contributor.author | Reuss, Annicka | |
dc.contributor.author | Rizzo, Caterina | |
dc.contributor.author | Larrauri, Amparo | |
dc.contributor.author | Horváth, Judit Krisztina | |
dc.contributor.author | Brytting, Mia | |
dc.contributor.author | Domegan, Lisa | |
dc.contributor.author | Korczyńska, Monika | |
dc.contributor.author | Meijer, Adam | |
dc.contributor.author | Machado, Ausenda | |
dc.contributor.author | Ivanciuc, Alina | |
dc.contributor.author | Višekruna Vučina, Vesna | |
dc.contributor.author | van der Werf, Sylvie | |
dc.contributor.author | Schweiger, Brunhilde | |
dc.contributor.author | Bella, Antonino | |
dc.contributor.author | Gherasim, Alin Manuel | |
dc.contributor.author | Ferenczi, Annamária | |
dc.contributor.author | Zakikhany, Katherina | |
dc.contributor.author | O Donnell, Joan | |
dc.contributor.author | Paradowska-Stankiewicz, Iwona | |
dc.contributor.author | Dijkstra, Frederika | |
dc.contributor.author | Guiomar, Raquel | |
dc.contributor.author | Lazar, Mihaela | |
dc.contributor.author | Kurečić Filipović, Sanja | |
dc.contributor.author | Johansen, Kari | |
dc.contributor.author | Moren, Alain | |
dc.date.accessioned | 2020-04-28T08:27:22Z | |
dc.date.available | 2020-04-28T08:27:22Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Influenza Other Respir Viruses. 2018 Jul;12(4):423-437. | es_ES |
dc.identifier.issn | 1750-2640 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9770 | |
dc.description.abstract | BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. | es_ES |
dc.description.sponsorship | ECDC has contributed fund for the coordination and some study sites under the Framework contract no. ECDC/2014/026 for the individuals aged less than 65 years. The I‐MOVE/I‐MOVE+ study team is very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams and regional epidemiologists who have contributed to the study. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website http://www.gisaid.org. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Case-control study | es_ES |
dc.subject | Influenza | es_ES |
dc.subject | Influenza vaccine | es_ES |
dc.subject | Multicentre study | es_ES |
dc.subject | Vaccine effectiveness | es_ES |
dc.subject.mesh | Adolescent | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Case-Control Studies | es_ES |
dc.subject.mesh | Child | es_ES |
dc.subject.mesh | Child, Preschool | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Infant | es_ES |
dc.subject.mesh | Influenza A Virus, H1N1 Subtype | es_ES |
dc.subject.mesh | Influenza B virus | es_ES |
dc.subject.mesh | Influenza Vaccines | es_ES |
dc.subject.mesh | Influenza, Human | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Young Adult | es_ES |
dc.title | 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 29125681 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | 423-437 | es_ES |
dc.identifier.doi | 10.1111/irv.12520 | es_ES |
dc.contributor.funder | Unión Europea. European Centre for Disease Prevention and Control (ECDC) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1750-2659 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1111/irv.12520 | es_ES |
dc.identifier.journal | Influenza and other respiratory viruses | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/ECDC/2014/026 | es_ES |
dc.rights.accessRights | open access | es_ES |